# EDGAR Filing Document

**Accession Number:** 0000890821
**File Stem:** 0000000000-26-004265
**Filing Date:** 2026-4
**Character Count:** 2455
**Document Hash:** a5b0c8a4015270e84c633091375dae00
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-004265.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0000000000-26-004265

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260427

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enveric Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0000890821
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 954484725
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-295273

**BUSINESS ADDRESS:**
- **STREET 1:** 245 FIRST STREET RIVERVIEW II 18TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** (617) 444-8400

**MAIL ADDRESS:**
- **STREET 1:** 245 FIRST STREET RIVERVIEW II 18TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERI Holdings, Inc.
- **DATE OF NAME CHANGE:** 20150527

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPATIALIZER AUDIO LABORATORIES INC
- **DATE OF NAME CHANGE:** 19950323
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-26-018724

## Text-Extract

```

                                                           April 27, 2026

Joseph Tucker, Ph.D.
Chief Executive Officer
Enveric Biosciences, Inc.
245 First Street, Riverview II, 18th Floor
Cambridge MA, 02142

        Re: Enveric Biosciences, Inc.
            Registration Statement on Form S-3
            Filed April 23, 2026
            File No. 333-295273
Dear Joseph Tucker, Ph.D.:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Rasika A. Kulkarni, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._